P2-VP8 subunit vaccine

The P2-VP8 subunit vaccine is a non-replicating, recombinant protein subunit vaccine developed by PATH for the prevention of rotavirus gastroenteritis. Unlike traditional oral live-attenuated rotavirus vaccines, this candidate is administered parenterally via intramuscular injection, which may improve efficacy in low-income settings where oral vaccines often underperform. The vaccine is composed of a truncated VP8 subunit protein derived from the rotavirus outer capsid spike protein VP4, fused to a universal T-cell epitope (P2) from tetanus toxin to enhance the immune response. It is expressed in Escherichia coli and formulated with an aluminum hydroxide adjuvant (Alhydrogel). The vaccine has been developed in both monovalent (targeting the P[8] genotype) and trivalent (targeting P[4], P[6], and P[8] genotypes) formulations, and clinical trials have demonstrated its safety and immunogenicity in infants and toddlers.

Other names

P2-VP8 subunit parenteral rotavirus vaccineP-2-VP8 subunit parenteral rotavirus vaccineP 2-VP8 subunit parenteral rotavirus vaccineP2-VP8-P[8] monovalent vaccineP2-VP8-P[4],[6],[8] trivalent vaccine